FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical field and deals with perorally bioavailable pharmaceutical composition, which contains (a) CETP inhibiting compound, which has formula 
, or its pharmaceutically acceptable salt: (b) concentration-increasing polymer and (c) optionally one or more surface active substances. Invention also relates to application of said composition for production of medication, which increases level of HDL-cholesterol in patient.
EFFECT: invention provides compositions, which increase level of HDL-cholesterol and characterised by improved bioavailability in introduction to patient.
20 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS OF SOLID DOSAGE FORMS OF OREXIN RECEPTOR ANTAGONIST | 2013 |
|
RU2759837C2 |
| COMPOSITIONS OF SOLID DOSAGE FORMS OF AN OREXIN RECEPTOR ANTAGONIST | 2013 |
|
RU2699358C2 |
| COMPOSITION OF THE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | 2014 |
|
RU2661399C1 |
| DOSAGE FORMS WITH RETARDED RELEASE OF ZIPRASIDONE | 2004 |
|
RU2351316C2 |
| PHARMACEUTICAL COMPOSITION POSSESSING ANTI-PROLIFERATIVE EFFECT (VARIANTS), METHOD FOR ITS PREPARING AND METHODS FOR ITS USING | 2003 |
|
RU2318518C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLE DERIVATIVES | 2006 |
|
RU2413504C2 |
| PROCESS FOR PREPARING HOMOGENOUS SPRAY-DRIED SOLID AMORPHOUS THERAPEUTICAL DISPERSE SYSTEMS USING SPRAYING PRESSURE NOZZLES (OPTIONS) AND PRODUCT | 2003 |
|
RU2288703C2 |
| SOLID DISPERSIONS | 2016 |
|
RU2694832C2 |
| PHARMACEUTICAL PREPARATION | 2017 |
|
RU2760681C2 |
| PHARMACEUTICAL COMPOSITION IN FORM OF SINGLE ORAL DOSE CONTAINING LEVODOPA, CARBIDOPA AND ENTACAPONE, OR SALTS THEREOF | 2009 |
|
RU2519159C2 |
